- Conditions
- Mesial Temporal Lobe Epilepsy
- Interventions
- Low Frequency Stimulation (LFS) of site with the Medtronic Percept PC system, Standard of Care (SOC) High Frequency Stimulation of the Anterior Nucleus of the Thalamus (ANT) with the Medtronic Percept PC system
- Device
- Lead sponsor
- Nitin Tandon
- Other
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 8 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2029
- U.S. locations
- 2
- States / cities
- Rochester, Minnesota • Houston, Texas
Clinical trials at Mayo Clinic
Sites in Rochester, MN
Institution pages show live ClinicalTrials.gov records that list this campus as a study site, whoever sponsors them. They do not rate, rank, or describe the institution.
All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
Live official records
Study of 225Ac-ABD147 to Establish Optimal Dose in Patients With SCLC and LCNEC of the Lung That Previously Received Platinum-based Chemotherapy
- Conditions
- Small-Cell Lung Cancer (SCLC), Large Cell Neuroendocrine Carcinoma of the Lung
- Interventions
- 225Ac-ABD147
- Drug
- Lead sponsor
- Abdera Therapeutics Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 17 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2027
- U.S. locations
- 12
- States / cities
- Newport Beach, California • San Francisco, California • Santa Monica, California + 9 more
Radiotherapy Compared to Corticosteroid Injection for Treatment of Hand Osteoarthritis
- Conditions
- Osteoarthritis Hand, Osteoarthritis Wrist
- Interventions
- Corticosteroid injection (CSI), Low-dose radiotherapy (LDRT)
- Drug · Radiation
- Lead sponsor
- Mayo Clinic
- Other
- Eligibility
- 50 Years and older
- Enrollment
- 165 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2027
- U.S. locations
- 1
- States / cities
- Rochester, Minnesota
Detection of Plasma DNA Methylation in Peripheral Blood From Patients With Resectable Liver Cancer
- Conditions
- Resectable Hepatocellular Carcinoma
- Interventions
- Biospecimen Collection, Electronic Health Record Review
- Procedure · Other
- Lead sponsor
- Mayo Clinic
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 36 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2029
- U.S. locations
- 1
- States / cities
- Rochester, Minnesota
Real World Registry for Use of the Ion Endoluminal System
- Conditions
- Lung Cancer, Multiple Pulmonary Nodules, Lung Neoplasms, Respiratory Tract Neoplasms, Thoracic Neoplasms, Neoplasms by Site, Neoplasms, Lung Diseases, Respiratory Tract Diseases
- Interventions
- Ion Endoluminal System
- Device
- Lead sponsor
- Intuitive Surgical
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 1,301 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2028
- U.S. locations
- 16
- States / cities
- Orlando, Florida • Elk Grove Village, Illinois • Quincy, Illinois + 13 more
Endocrine Therapy With or Without Abemaciclib (LY2835219) Following Surgery in Participants With Breast Cancer
- Conditions
- Breast Cancer
- Interventions
- Abemaciclib, Standard Adjuvant Endocrine Therapy
- Drug
- Lead sponsor
- Eli Lilly and Company
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 5,637 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2029
- U.S. locations
- 162
- States / cities
- Birmingham, Alabama • Anchorage, Alaska • Gilbert, Arizona + 104 more
De-Escalation of Breast Radiation Trial for Hormone Sensitive, HER-2 Negative, Oncotype Recurrence Score Less Than or Equal to 18 Breast Cancer (DEBRA)
- Conditions
- Stage I Breast Cancer
- Interventions
- Radiation and Endocrine Therapy (Tamoxifen, Anastrozol, Letrozole, Exemestane), Endocrine Therapy (Tamoxifen, Anastrozol, Letrozole, Exemestane)
- Other · Drug
- Lead sponsor
- NRG Oncology
- Other
- Eligibility
- 50 Years to 70 Years
- Enrollment
- 1,670 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2041
- U.S. locations
- 812
- States / cities
- Birmingham, Alabama • Mobile, Alabama • Kingman, Arizona + 553 more
- Conditions
- Scoliosis
- Interventions
- Video recording of clinical visit
- Other
- Lead sponsor
- Mayo Clinic
- Other
- Eligibility
- 13 Years and older
- Enrollment
- 25 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2027
- U.S. locations
- 1
- States / cities
- Rochester, Minnesota
Determination of Baseline Levels for Prostate Cancer-Derived Extracellular Vesicles Following Local Treatment of Prostate Cancer
- Conditions
- Prostate Carcinoma
- Interventions
- Non-Interventional Study
- Other
- Lead sponsor
- Mayo Clinic
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 98 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2020 – 2026
- U.S. locations
- 1
- States / cities
- Rochester, Minnesota
MElanoma Research Lymph Node Prediction Implementation National_001
- Conditions
- Melanoma
- Interventions
- Not listed
- Lead sponsor
- SkylineDx
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 1,820 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2029
- U.S. locations
- 9
- States / cities
- Tampa, Florida • Atlanta, Georgia • Lexington, Kentucky + 6 more
Study to Investigate the Efficacy and Safety of RP1 in Adult Patients With Organ Transplants and Advanced Skin Malignancies
- Conditions
- Merkel Cell Carcinoma, Basal Cell Carcinoma, Locally Advanced Cutaneous Squamous Cell Carcinoma, Cancer
- Interventions
- RP1, intra-tumoral injection, oncolytic virus
- Biological
- Lead sponsor
- Replimune, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 69 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2029
- U.S. locations
- 24
- States / cities
- Phoenix, Arizona • La Jolla, California • Los Angeles, California + 20 more
- Conditions
- Central Nervous System Neoplasm
- Interventions
- Biospecimen Collection, Electronic Health Record Review
- Procedure · Other
- Lead sponsor
- Mayo Clinic
- Other
- Eligibility
- Not listed
- Enrollment
- 400 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2028
- U.S. locations
- 1
- States / cities
- Rochester, Minnesota
About this Mayo Clinic institution page
- What this page lists
- ClinicalTrials.gov records that list Mayo Clinic in Rochester, MN as a study site, whoever sponsors them, among recruiting, not yet recruiting, and active not recruiting trials.
- Site status
- A study's overall status can differ from this site's status. Sites marked withdrawn, terminated, or completed are not counted here. Each record shows the status listed for this site when the official record provides one.
- Where the data comes from
- Records are sourced from the official ClinicalTrials.gov public API. Each result links back to the official study page, which is the source of truth for eligibility, enrollment, and contact information.
- What this page does not do
- No medical advice, eligibility judgments, ranking of trials, or AI-generated medical summaries. This page does not rank or rate institutions.
Related: all institution pages, trials led by Mayo Clinic at any site, browse by condition, or browse by U.S. city.